Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000376736

Medchemexpress LLC Imatinib-d4 (STI571 d4; CGP-57148B d4) | 1134803-16-9 | C29H27D4N7O | 1 MG
SDP

Catalog No. 5000376736
Encompass_Preferred

Imatinib-d4 (STI571-d4) is a deuterium-labeled version of Imatinib (STI571), an orally bioavailable tyrosine kinase inhibitor. It selectively targets and inhibits the activity of BCR/ABL, v-Abl, PDGFR, and c-kit kinases, and is intended for research use only. This compound serves as a tracer and an internal standard for quantitative analysis, leveraging stable heavy isotopes like deuterium to potentially influence pharmacokinetic and metabolic profiles of drugs.

  • Can be used as a tracer
  • Can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS
  • Stable heavy isotopes of hydrogen, carbon, and other elements incorporated into drug molecules largely serve as tracers for quantitation during drug development
  • Deuteration can affect pharmacokinetic and metabolic profiles of drugs

Catalog No. 50-003-76736 Supplier Medchemexpress LLC Supplier No. HY15463S11MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Imatinib-d4 (STI571-d4) is a deuterium-labeled version of Imatinib (STI571), an orally bioavailable tyrosine kinase inhibitor. It selectively targets and inhibits the activity of BCR/ABL, v-Abl, PDGFR, and c-kit kinases, and is intended for research use only. This compound serves as a tracer and an internal standard for quantitative analysis, leveraging stable heavy isotopes like deuterium to potentially influence pharmacokinetic and metabolic profiles of drugs.

  • Can be used as a tracer
  • Can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS
  • Stable heavy isotopes of hydrogen, carbon, and other elements incorporated into drug molecules largely serve as tracers for quantitation during drug development
  • Deuteration can affect pharmacokinetic and metabolic profiles of drugs

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.